The Wistar Institute Biomedical Technician Training (BTT) Program was awarded Workforce Champion of the Year in the 3rd Annual 2022 BioBuzz Awards. The program is a collaborative that includes The Wistar Institute, West Philadelphia Skills Initiative, Iovance Biotherapeutics, PIDC, and others.
The Wistar Insitute, William Way Community Center, Philadelphia FIGHT, BEAT-HIV Delaney Collaboratory, Philadelphia Foundation, and The Penn Center for AIDS Research are proud to announce that “The London Patient” Adam Castillejo will take part in a panel conversation and Q&A on Wednesday, October 26 from 5 to 8 pm
In a research paper published in PLOS ONE, The Wistar Institute's Dario C. Altieri, M.D., alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
The National Institutes of Health has awarded Amelia Escolano, Ph.D., assistant professor in The Wistar Institute’s Vaccine & Immunotherapy Center, the 2022 NIH Director’s New Innovator Award.
Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. However, new research out of The Wistar Institute now provides evidence of novel, reliable biomarkers that predict therapy response using advanced computer technology.
The Wistar Institute is pleased to announce the appointment of Michele A. Schiavoni, M.S., as Vice President of Communications & Marketing, in a central leadership role that will bolster the visibility of the Institute’s ambitious biomedical research science initiatives and programs advancing the organization’s newly launched Bold Science // Global Impact Capital Campaign.
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments.
The National Cancer Institute (NCI) has granted a Merit Extension Award to The Wistar Institute’s Ellen and Ronald Caplan Cancer Center totaling more than $5 million.
Published today in Nature Cell Biology, Wistar scientists revealed a novel ADAR1-SIRT1-p16INK4a axis in regulating cellular senescence and its potential implications in tissue aging.
The Wistar Institute announces the appointment of Gelvina Rodriguez Stevenson, Esq., as vice president, general counsel, secretary and government relations.
Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.
Wistar announces that for the first time it will globally stream its 26th Annual Jonathan Lax Memorial Award Lecture, celebrating 26 years of providing state-of-research updates to the community, on Tuesday, June 28 from 9:30 to 11:00 a.m. EST.
Wistar scientists identified that inhibiting therapeutic target KDM5A boosts a person’s immune response to tumors.
Wistar Institute announces its Bold Science // Global Impact Capital Campaign to support a five-year plan that sets out Wistar’s roadmap for accelerated progress to drive breakthroughs in biomedical science and technology and educate and train the next generation of innovators.
Wistar Institute scientists take a promising step in the direction of developing an HIV vaccine that uses a unique native-like trimer to develop Tier-2 neutralizing antibodies—the kind that matter for combatting HIV—in mice for the first time.
The first generation of COVID-19 vaccines have been highly effective, but also have limitations. Now Wistar scientists have developed a more targeted vaccine that, in animal studies, shows stronger, broader, and more durable protection in a single, low dose.
A new study by Wistar researchers has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).
Wistar announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.
Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer.
Scientists at The Wistar Institute have identified two genes that play a critical role in protecting ovarian cancer from the immune system.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right